Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heparin Crisis Spurs Changes In FDA Emergency Response Policies

Executive Summary

Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.

You may also be interested in...



Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate

Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.

Heparin Crisis Leads To New FDA Policy On Consulting Outside Experts

A Government Accountability Office report criticizing FDA's retention of outside experts on heparin contamination spurs disclosure and conflict-of-interest screening policies for emergency situations.

Elections Reshape FDA Oversight Scene On Capitol Hill

The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel